184 related articles for article (PubMed ID: 17762615)
1. Use of tumor necrosis factor inhibitors in uveitis.
Rabinovich CE
Curr Opin Rheumatol; 2007 Sep; 19(5):482-6. PubMed ID: 17762615
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
3. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.
Saurenmann RK; Levin AV; Feldman BM; Laxer RM; Schneider R; Silverman ED
J Pediatr; 2006 Dec; 149(6):833-6. PubMed ID: 17137902
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood].
Heiligenhaus A; Horneff G; Greiner K; Mackensen F; Zierhut M; Foeldvari I; Michels H
Klin Monbl Augenheilkd; 2007 Jun; 224(6):526-31. PubMed ID: 17594625
[TBL] [Abstract][Full Text] [Related]
5. Favorable response to high-dose infliximab for refractory childhood uveitis.
Kahn P; Weiss M; Imundo LF; Levy DM
Ophthalmology; 2006 May; 113(5):860-4.e2. PubMed ID: 16545455
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
[TBL] [Abstract][Full Text] [Related]
7. TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? - an evidence based approach.
Winterhalter S; Niehues T
Klin Padiatr; 2008; 220(6):342-7. PubMed ID: 18949668
[TBL] [Abstract][Full Text] [Related]
8. Surgery for hypotony in patients with juvenile idiopathic arthritis-associated uveitis.
Yu EN; Paredes I; Foster CS
Ocul Immunol Inflamm; 2007; 15(1):11-7. PubMed ID: 17365801
[TBL] [Abstract][Full Text] [Related]
9. Pediatric rheumatology for the adult rheumatologist II: uveitis in juvenile idiopathic arthritis.
Wright T; Cron RQ
J Clin Rheumatol; 2007 Aug; 13(4):205-10. PubMed ID: 17762455
[TBL] [Abstract][Full Text] [Related]
10. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease.
Sharma SM; Ramanan AV; Riley P; Dick AD
Ann Rheum Dis; 2007 Jun; 66(6):840-1. PubMed ID: 17170050
[No Abstract] [Full Text] [Related]
11. Biologics in the treatment of uveitis.
Imrie FR; Dick AD
Curr Opin Ophthalmol; 2007 Nov; 18(6):481-6. PubMed ID: 18163000
[TBL] [Abstract][Full Text] [Related]
12. [Anti-TNFalpha treatment of juvenile uveitis].
Fledelius HC; Nielsen SM; Nissen KR; Pedersen FK; Zak MS
Ugeskr Laeger; 2007 Apr; 169(14):1309-12. PubMed ID: 17437693
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor-α agents in noninfectious uveitis.
Gueudry J; LeHoang P; Bodaghi B
Dev Ophthalmol; 2012; 51():63-78. PubMed ID: 22517205
[TBL] [Abstract][Full Text] [Related]
14. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
15. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis.
Zulian F; Balzarin M; Falcini F; Martini G; Alessio M; Cimaz R; Cimino L; Zannin ME
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):821-5. PubMed ID: 20191477
[TBL] [Abstract][Full Text] [Related]
16. Update on biologics in juvenile idiopathic arthritis.
Ilowite NT
Curr Opin Rheumatol; 2008 Sep; 20(5):613-8. PubMed ID: 18698187
[TBL] [Abstract][Full Text] [Related]
17. Biological response modifier therapy for refractory childhood uveitis.
Gallagher M; Quinones K; Cervantes-Castañeda RA; Yilmaz T; Foster CS
Br J Ophthalmol; 2007 Oct; 91(10):1341-4. PubMed ID: 17556427
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis.
Sijssens KM; Rothova A; Van De Vijver DA; Stilma JS; De Boer JH
Am J Ophthalmol; 2007 Oct; 144(4):574-9. PubMed ID: 17706583
[TBL] [Abstract][Full Text] [Related]
19. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.
Kotter I; Deuter C; Stubiger N; Zierhut M
J Rheumatol; 2005 Aug; 32(8):1633; author reply 1634. PubMed ID: 16078350
[No Abstract] [Full Text] [Related]
20. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital.
Petropoulos IK; Vaudaux JD; Guex-Crosier Y
Klin Monbl Augenheilkd; 2008 May; 225(5):457-61. PubMed ID: 18454398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
